Julie Parsons, MD, and John Brandsema, MD, open a discussion surrounding prevalence of spinal muscular atrophy (SMA).
Highlighting Rare Disease: Spinal Muscular Atrophy (SMA) Management Considerations
Disease-modifying agents play a significant role in treatment strategies for patients with SMA.
Julie Parsons, M.D., and John Brandsema, M.D., explore economic burdens associated with SMA.
Medical experts illustrate characteristics in the presentation of lupus nephritis.
Disease-modifying treatments are highlighted as key contributors to the optimization of SMA management.
Medical experts provide insights on factors impacting SMA treatment strategies.
John Brandsema, MD, and Julie Parsons, MD, discuss considerations for combination SMA treatment and factors impacting SMA care pathways, such as prior authorization and multistep therapies.
In their final thoughts, Julie Parsons, MD, and John Brandsema, MD, share insights on the evolving and future SMA treatment landscape.
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
FDA tentatively approves first generic lenacapavir for HIV prevention in lower-income countries
2
New pulmonary fibrosis drugs put guidelines in focus, Prusi says | AMCP Nexus 2026
3
Fewer than half of newly diagnosed children with type 1 diabetes get autoantibody testing
4
Targeted therapies for atopic dermatitis reduce hospitalizations and ER visits, but cost is a different story
5